Type17 T-cells in central nervous system autoimmunity and tumors

Journal of Clinical Immunology

Volumn 32, Issue 4, 2012, Pages 802-808

  Okada, Hideho ^a,b   Khoury, Samia J ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Adoptive transfer therapy; Autoimmunity; Central nervous system; Gliomas; IL 17; Multiple sclerosis; Th17

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR3; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CELL MIGRATION; CENTRAL NERVOUS SYSTEM TUMOR; CYTOKINE PRODUCTION; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL MOVEMENT; GLIOMA; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; MICE; MULTIPLE SCLEROSIS; TH17 CELLS;

EID: 84863988286     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9686-z     Document Type: Article

References (53)

1. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer[mdash]what clinicians need to know. Nat Rev Clin Oncol. 2011;8:577-85.
2. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establishmemory in patients with advanced Leukemia. Sci Transl Med. 2011;3:95ra73.
3. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor- modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-33.
4. Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med. 2006;354:758-60. (Pubitemid 43247149)
5. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-18. (Pubitemid 43247141)
6. Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol
7. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1-13.
8. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010;5:189-97.
9. Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol. 1989;124:132-43. (Pubitemid 20000271)
10. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1 + 2- T lymphocytes. J Immunol. 1981;127:1420-3. (Pubitemid 11021014)
11. Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol. 1996;157:3223-7. (Pubitemid 126449130)
12. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566-73. (Pubitemid 43939170)
13. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Investig. 2009;119:61-9.
14. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic Tcell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-40. (Pubitemid 40189432)
15. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10:514-23.
16. Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. 2008;205:1535-41. (Pubitemid 351962016)
17. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med. 2008;14:337-42. (Pubitemid 351347910)
18. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173-5. (Pubitemid 47530640)
19. Yamazaki T, Yang XO, Chung Y, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol. 2008;181:8391-401.
20. Hirota K, Yoshitomi H, HashimotoM, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803-12. (Pubitemid 350179551)
21. Kohler RE, Caon AC, Willenborg DO, et al. A role for macrophage inflammatory protein-3a/CC chemokine ligand 20 in immune priming during T cell-mediated inflammation of the central nervous system. J Immunol. 2003;170:6298-306. (Pubitemid 36682616)
22. Liston A, Kohler RE, Townley S, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol. 2009;182:3121-30.
23. Hedegaard CJ, Krakauer M, Bendtzen K, et al. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008;125:161-9.
24. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease inmultiple sclerosis.AmJ Pathol. 2008;172:146-55. (Pubitemid 351186376)
25. Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain: J Neurol. 2009;132:3329-41.
26. Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549-64.
27. Abromson-Leeman S, Bronson RT, Dorf ME. Encephalitogenic T cells that stably express both T-bet and ROR?t consistently produce IFN? but have a spectrum of IL-17 profiles. J Neuroimmunol. 2009;215:10-24.
28. Suryani S, Sutton I. An interferon-?-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol. 2007;183:96-103. (Pubitemid 46204914)
29. Murphy AC, Lalor SJ, Lynch MA, et al. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24:641-51.
30. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639-46. (Pubitemid 46785128)
31. Maniati E, Soper R, Hagemann T. Up for Mischief[quest] IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29:5653-62.
32. Wilke CM, Kryczek I, Wei S, et al. Th17 cells in cancer: Help or hindrance? Carcinogenesis. 2011;32:643-9.
33. Zou W, Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10:248-56.
34. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141-9.
35. Murphy KM, Stockinger B. Effector Tcell plasticity: flexibility in the face of changing circumstances. Nat Immunol. 2010;11:674-80.
36. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 2010;40:3312-6.
37. Martin-Orozco N, Chung Y, Chang SH, et al. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009;39:216-24.
38. Bending D, De La Peña H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Investig. 2009;119:565-72.
39. Nistala K, Adams S, Cambrook H, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci. 2010;107:14751-6.
40. Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res. 2008;14:3254-61.
41. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-9. (Pubitemid 39273735)
42. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17- polarized cells eradicate large established melanoma. Blood. 2008;112:362-73.
43. Hinrichs CS, Kaiser A, Paulos CM, et al. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 2009;114:596-9.
44. Martin-Orozco N, Muranski P, Chung Y, et al. T Helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787-98.
45. Paulos CM, Carpenito C, Plesa G, et al. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci Transl Med. 2010;2:55ra78.
46. Garcia-Hernandez MdlL, Hamada H, Reome JB, et al. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol. 2010;184:4215-27.
47. Muranski P, Borman ZA, Kerkar SP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011.
48. Hamai A, Pignon P, Raimbaud I, et al. Human Th17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-? secreting cells as they differentiate into effector Tcells in vivo. Canc Res. 2012 48. Hamai A, Pignon P, Raimbaud I, et al. Human Th17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-? secreting cells as they differentiate into effector Tcells in vivo. Canc Res. 2012.
49. Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010;5:e15390.
50. Cantini G, Pisati F, Mastropietro A, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Canc Immunol Immunother. 2011;60:1739-50.
51. Schwartzbaum JA, Huang K, Lawler S, et al. Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro-Oncology. 2010;12:320-7.
52. Hu J, Mao Y, Li M, et al. The profile of Th17 subset in glioma. Int Immunopharmacol. 2011;11:1173-9.
53. Zhou P, Sha H, Zhu J. The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res. 2010;38:611-9.